T. Forcht (Teo) Dagi, MD, MPH, DMedSc, MBA, Managing Partner, is a neurosurgeon and neuro-intensivist, and a veteran venture capitalist with extensive international experience in public service. He has helped raise over $500 million in funds for portfolio companies and venture capital funds and has more than 15 years of successful experience in founding, managing and exiting companies in health care services and in the life sciences. He has operating experience in healthcare services, healthcare information technology and the biomedical sector, and he has served on boards of directors of publicly traded and privately held companies. Dr. Dagi serves as Honourary Professor, and Chairman of International Advisory Panel of the School of Medicine of Queen’s University Belfast, Northern Ireland (UK), and Visiting Professor at Harvard Medical School. He chairs the Committee on Perioperative Care of the American College of Surgery and serves as a Director of the Council for Surgical and Perioperative Safety and the Anesthesia Patient Safety Foundation. He lectures in the Harvard Business School on healthcare innovation and in the Biomedical Entrepreneurship Program at the Harvard-MIT Program in Health Sciences and Technology on new technology development, assessment, and commercialization. Dr. Dagi received an AB from Columbia University, his MD and MPH degrees from Johns Hopkins, and an MBA from the Wharton School. He was named the Joseph P. Kennedy, Jr., Fellow at Harvard, from which he also received a MTS degree in jurisprudence. He trained at the Massachusetts General Hospital and the Neurosurgical Unit of the Guy’s, Maudsley and King’s College Hospitals in London. He was President of the Georgia Neurosurgical Society and a Director of the American Association of Neurological Surgeons. Among other distinctions, he has been awarded the US Humanitarian Service Medal, and a DMedSc (Hon. Causae) from Queen’s University for contributions to medicine and public service. He was named the Sir Thomas and Edith Dixon Medalist for 2012 and was named to an ad hominem Fellowship in the Royal College of Surgeons Edinburgh in 2013. He is an editor of Neurosurgery and the Journal of Clinical Ethics, has published over 175 articles and co-authored or edited several books.
Russell M. Medford, MD, PhD, Managing Partner is a senior biotechnology executive with extensive private and public company experience as Chief Executive Officer and Board member of multiple biotechnology and other health related companies, organizations and research institutes. From 1995 to 2009, Dr. Medford served as co-founder, President, CEO and Director of publicly-held AtheroGenics, Inc (Nasdaq: AGIX) and from 2009 to 2012 CEO and Chairman of Salutria Pharmaceuticals, LLC. He was a founding Board Director of publicly-held Inhibitex, Inc. (Nasdaq: INHX) until it was acquired by Bristol-Myers-Squibb in 2012 for $2.5 billion. He has had extensive experience leading companies and organizations engaged in comprehensive therapeutic drug research and development, developing multiple, novel, first-in-man clinical candidates for the treatment of cardiovascular disease, diabetes and arthritis, conducted multiple phase I, II and III clinical studies involving over 400 clinical trial sites in 12 countries, including the US, UK, Canada, South Africa, India, Russia, Eastern Europe and India involving more than 7000 patients, executed multiple strategic partnerships with major pharmaceutical companies including Schering-Plough, Fujisawa and AstraZeneca, as well as building a commercial-scale, manufacturing plant for lead, small-molecule pharmaceutical agents. He has extensive experience in both the private and public financial markets including initial public offerings (IPO) raising over $500 million for corporate, clinical development and research programs. He has served on multiple private company Boards including Transcardiac Therapeutics, Inc., Somatocor, Inc. and EmTech Bio. He is a board-certified physician, an inaugural Fellow of the Council on Basic Cardiovascular Sciences of the American Heart Association, a member of the executive committee and former Chairman of GeorgiaBio, a member of Biotechnology Industry Organization’s (BIO) Board of Directors, Emerging Companies Section Governing Board and Health Science Governing Board, Co-Chairman of BIO’s Bioethics Committee and served as Chairman of the BIO's 2009 International Convention Steering Committee. Dr. Medford is a past member of the Advisory Council of the National Heart, Lung and Blood Institute and currently serves on the Board of Trustees of the National Health Museum and Chairman of the External Advisory Board for the Petit Institute of Bioscience and Bioengineering of the Georgia Institute of Technology. He has received numerous awards including the Ernst and Young Entrepreneur of the Year Award (Southeast), the Biomedical Industry Growth Award (Georgia Bio), CATALYST Magazine's Top 50 Entrepreneurs and the SCRIPP Best Partnership Alliance (London). Dr. Medford also serves as Chairman of Artetude Gallery, Inc., a private, North Carolina contemporary fine art company based in Asheville. Dr. Medford was an Associate Professor of Medicine, Director of Molecular Cardiology and Adjunct Clinical Professor of Medicine at the Emory University School of Medicine where he founded Atherogenics, Inc. He received a B.A. from Cornell University, and a M.D. with Distinction and a Ph.D. in Molecular and Cell Biology from the Albert Einstein College of Medicine, completing his residency and cardiology fellowship at Harvard’s Beth Israel and Brigham and Women’s Hospitals where he also served on the faculty of Medicine. He publishes widely and holds over 16 U.S. and international patents.
Margaret K Offermann, MD, PhD, Managing Partner, is a medical oncologist and biomedical researcher who has extensive senior leadership experience in academic, philanthropic and private healthcare settings. She is past President for the Federation of American Societies for Experimental Biology (FASEB), a non-profit federation of 26 professional societies focused on the life sciences that collectively have over 100,000 members. FASEB serves as a major voice for the biomedical research community on Capital Hill and in policy settings. She is on the Board of Directors of Georgia Center for Research and Education (GaCORE), a non-profit organization that promotes cooperation between cancer clinicians, educators and researchers throughout the state of Georgia. She served as co-chair of the Committee of Scientific Researchers for Georgia Bio, helping scientists in academia and industry work together to advance promising discoveries with commercial potential. From 1989 to 2007, she served on the faculty of Emory University School of Medicine where she rose to the rank of Professor of Hematology and Oncology and served as co-director of the MD-PhD training program, Associate Director of the Postgraduate Training Program in Hematology and Oncology and Associate Director of the Winship Cancer Institute. Her research program explored innate antiviral immunity in endothelial cells and the molecular events in the pathogenesis of Kaposi's sarcoma, with funding from the National Institutes of Health, the American Cancer Society, the American Heart Association and other organizations. From 2007-2010, she served as Deputy National Vice President for Research at the American Cancer Society, providing executive leadership for both intramural and extramural research programs for the largest non-profit, non-government funder of cancer research in the US. Through Salutramed Group, Inc, she served as founding medical director of the Mission Health System Cancer Center in Asheville, NC, a heath system rated by Reuters as one of the top 15 in the nation in 2012. She received a BA in biochemistry from Mount Holyoke College, magna cum laude and her MD and PhD in biochemistry from the Medical College of Virginia. She did internship and residency in Internal Medicine at the University of Chicago Hospitals followed by training in Medical Oncology at the Dana Farber Cancer Institute and Harvard Medical School in Boston. She is board certified in Medical Oncology and Internal Medicine.
Kenneth I. Moch, Managing Partner, has broad expertise building, managing and financing private and public life science companies from start-up through commercialization, and has helped build five companies which have pioneered novel technologies. Ken has served as President & CEO of four life science companies: Chimerix, Inc. (NASDAQ:CMRX), a public antiviral therapeutics company which is developing brincidofovir as the first broad spectrum agent against DNA viruses; BioMedical Enterprises, a manufacturer and marketer of nitinol orthopedic implants; Alteon, Inc., a developer of small molecule therapeutics for cardiovascular aging and diabetic complications; and Biocyte Corporation, where he pioneered the storage and therapeutic use of cord blood stem cells and launched the first cord blood stem cell storage bank. He was also a co-founder and Vice President of The Liposome Company, Inc., a pioneer in the use of liposomes for the delivery of anticancer and antifungal drugs. During the course of his career Ken has also been a Managing Director of Healthcare Investment Banking at ThinkEquity Partners and a management consultant with McKinsey & Company. Building on his longstanding interest in health policy, Ken served for over a decade on the Board of the Biotechnology Industry Organization (BIO), as Secretary of BIO’s Emerging Companies Section, and as a member of the BIO’s BioEthics Committee. He is a member of the Board of North Carolina Bio (NCBio), and is a past Chairman of Bio New Jersey (BioNJ) and a past member of the Executive Committee of the New York Biotechnology Association. Ken is a member of the NYU Working Group on Compassionate Use and Pre-Approval Access and recently joined the National Advisory Board of the Johns Hopkins Berman Institute of Bioethics. In August 2014, Ken and Arthur Caplan, the Head of Medical Ethics at NYU Medical Center, co-authored an article in Health Affairs on the ethical issues surrounding access to experimental medicines, "Rescue Me: The Challenge Of Compassionate Use In The Social Media Era." In March 2015 Ken contributed an Op-Ed to The Wall Street Journal entitled, “Wanted: Guidelines for Access to Experimental Drugs.” Ken currently serves on the Board of Zynerba, Inc., and as a member of the Board of M2Gen - Moffitt Genetics Corporation, the personalized medicine subsidiary of Moffitt Cancer Center. He holds an A.B. in biochemistry from Princeton University and an MBA from the Stanford University Graduate School of Business.